These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12610260)

  • 1. Public health. AIDS vaccine trial produces disappointment and confusion.
    Cohen J
    Science; 2003 Feb; 299(5611):1290-1. PubMed ID: 12610260
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV/AIDS. Vaccine results lose significance under scrutiny.
    Cohen J
    Science; 2003 Mar; 299(5612):1495. PubMed ID: 12624237
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical research. AIDS vaccine results draw investor lawsuits.
    Cohen J
    Science; 2003 Mar; 299(5615):1965. PubMed ID: 12663890
    [No Abstract]   [Full Text] [Related]  

  • 4. Vaccine participation urged for National Black AIDS Awareness month.
    AIDS Policy Law; 2006 Feb; 21(3):4. PubMed ID: 16509014
    [No Abstract]   [Full Text] [Related]  

  • 5. HIV vaccine fails in phase 3 trial.
    McCarthy M
    Lancet; 2003 Mar; 361(9359):755-6. PubMed ID: 12620743
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical research. A setback and an advance on the AIDS vaccine front.
    Cohen J
    Science; 2003 Apr; 300(5616):28-9. PubMed ID: 12677027
    [No Abstract]   [Full Text] [Related]  

  • 7. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.
    Omosa-Manyonyi G; Mpendo J; Ruzagira E; Kilembe W; Chomba E; Roman F; Bourguignon P; Koutsoukos M; Collard A; Voss G; Laufer D; Stevens G; Hayes P; Clark L; Cormier E; Dally L; Barin B; Ackland J; Syvertsen K; Zachariah D; Anas K; Sayeed E; Lombardo A; Gilmour J; Cox J; Fast P; Priddy F
    PLoS One; 2015; 10(5):e0125954. PubMed ID: 25961283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping the future of HIV vaccines.
    Nabel GJ
    Nat Rev Microbiol; 2007 Jul; 5(7):482-4. PubMed ID: 17571457
    [No Abstract]   [Full Text] [Related]  

  • 9. The race card. Does an HIV vaccine work differently in various races?
    Ezzell C
    Sci Am; 2003 May; 288(5):26. PubMed ID: 12701324
    [No Abstract]   [Full Text] [Related]  

  • 10. Vaccine research going back to square one.
    AIDS Read; 2008 Apr; 18(4):166, 208. PubMed ID: 18472426
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-chain peer referral to recruit black MSM and black transgender women for an HIV vaccine efficacy trial.
    Coombs A; McFarland W; Ick T; Fuqua V; Buchbinder SP; Fuchs JD
    J Acquir Immune Defic Syndr; 2014 Aug; 66(4):e94-7. PubMed ID: 24815850
    [No Abstract]   [Full Text] [Related]  

  • 12. HIV-1 risk and vaccine acceptability in the Ugandan military.
    Hom DL; Johnson JL; Mugyenyi P; Byaruhanga R; Kityo C; Louglin A; Svilar GM; Vjecha M; Mugerwa RD; Ellner JJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Aug; 15(5):375-80. PubMed ID: 9342258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Black people and the search for an HIV vaccine. A vaccine advocate gives us the low-down.
    Wakefield S
    Posit Aware; 2005; 16(6):30. PubMed ID: 16335467
    [No Abstract]   [Full Text] [Related]  

  • 14. Lessons for battle. A failed AIDS vaccine trial sheds new light on the disease.
    Fischer J
    US News World Rep; 2003 Mar; 134(7):54-5. PubMed ID: 12645474
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.
    Rolland M; Gilbert P
    AIDS Res Hum Retroviruses; 2012 Apr; 28(4):400-4. PubMed ID: 21902593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV vaccine may raise risk.
    Ledford H
    Nature; 2007 Nov; 450(7168):325. PubMed ID: 18004331
    [No Abstract]   [Full Text] [Related]  

  • 17. Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference.
    Ross AL; Bråve A; Scarlatti G; Manrique A; Buonaguro L
    Lancet Infect Dis; 2010 May; 10(5):305-16. PubMed ID: 20417413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial.
    Kahn JO; Steimer KS; Baenziger J; Duliege AM; Feinberg M; Elbeik T; Chesney M; Murcar N; Chernoff D; Sinangil F
    J Infect Dis; 1995 May; 171(5):1343-7. PubMed ID: 7751714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behavior, seroincidence, and willingness to participate.
    Buchbinder SP; Douglas JM; McKirnan DJ; Judson FN; Katz MH; MacQueen KM
    J Infect Dis; 1996 Nov; 174(5):954-61. PubMed ID: 8896495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.
    Robb ML; Rerks-Ngarm S; Nitayaphan S; Pitisuttithum P; Kaewkungwal J; Kunasol P; Khamboonruang C; Thongcharoen P; Morgan P; Benenson M; Paris RM; Chiu J; Adams E; Francis D; Gurunathan S; Tartaglia J; Gilbert P; Stablein D; Michael NL; Kim JH
    Lancet Infect Dis; 2012 Jul; 12(7):531-7. PubMed ID: 22652344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.